Spain's Sanifit Developing Unique Microcrystal Inhibitor For Calcification In Renal Disease
This article was originally published in Scrip
Executive Summary
Spain's fledgling life sciences biotech company Laboratoris Sanifit SL is developing a drug for vascular calcification that has a unique mode of action; it acts to inhibit pathological crystallization processes rather than targeting a receptor, enzyme or protein.